The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1

OBJECTIVE: There are few reports on the outcomes of 12-week paritaprevir, ombitasvir, and ritonavir (PTV/OBV/r) treatment in real-world clinical settings. We aimed to evaluate the efficacy and safety of 12-week treatment with ritonavir-boosted paritaprevir and ombitasvir in patients with hepatitis C...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyasaka, Akio, Yoshida, Yuichi, Yoshida, Toshimi, Murakami, Akihiko, Abe, Koichi, Ohuchi, Ken, Kawakami, Tadashi, Watanabe, Daisuke, Hoshino, Takao, Sawara, Kei, Takikawa, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207834/
https://www.ncbi.nlm.nih.gov/pubmed/29780135
http://dx.doi.org/10.2169/internalmedicine.0810-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207834/
https://www.ncbi.nlm.nih.gov/pubmed/29780135
http://dx.doi.org/10.2169/internalmedicine.0810-18

Ejemplares similares